Ingalls & Snyder LLC Purchases New Position in Thermo Fisher Scientific Inc. (TMO)
Ingalls & Snyder LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, Holdings Channel reports. The firm purchased 2,092 shares of the medical research company’s stock, valued at approximately $397,000.
Several other institutional investors have also made changes to their positions in the stock. Tealwood Asset Management Inc. boosted its holdings in Thermo Fisher Scientific by 5.5% in the 4th quarter. Tealwood Asset Management Inc. now owns 11,150 shares of the medical research company’s stock worth $2,117,000 after buying an additional 585 shares during the last quarter. TRUE Private Wealth Advisors acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $640,000. State of Alaska Department of Revenue boosted its holdings in Thermo Fisher Scientific by 587.2% in the 4th quarter. State of Alaska Department of Revenue now owns 42,671 shares of the medical research company’s stock worth $8,099,000 after buying an additional 36,462 shares during the last quarter. Swarthmore Group Inc. boosted its holdings in Thermo Fisher Scientific by 24.1% in the 4th quarter. Swarthmore Group Inc. now owns 51,450 shares of the medical research company’s stock worth $9,769,000 after buying an additional 10,000 shares during the last quarter. Finally, Westpac Banking Corp boosted its holdings in Thermo Fisher Scientific by 11.9% in the 4th quarter. Westpac Banking Corp now owns 269,839 shares of the medical research company’s stock worth $51,237,000 after buying an additional 28,600 shares during the last quarter. Hedge funds and other institutional investors own 86.25% of the company’s stock.
Several research analysts have recently weighed in on TMO shares. Leerink Swann boosted their target price on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a report on Monday, October 9th. Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. Barclays restated an “overweight” rating and set a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. Evercore ISI started coverage on Thermo Fisher Scientific in a report on Wednesday, January 3rd. They set an “outperform” rating and a $220.00 target price on the stock. Finally, Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 target price on the stock in a report on Tuesday, October 31st. Two equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Thermo Fisher Scientific has a consensus rating of “Buy” and an average price target of $212.21.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.03 EPS. analysts forecast that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Monday, January 15th. Stockholders of record on Friday, December 15th were given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.28%. The ex-dividend date was Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is presently 10.19%.
In other news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the sale, the chief executive officer now owns 302,577 shares of the company’s stock, valued at approximately $58,016,113.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.49% of the stock is currently owned by insiders.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.